|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 April 2002, Vol. 99, No. 7, pp. 2342-2350
GENE THERAPY
Efficient gene transfer into human primary blood lymphocytes by
surface-engineered lentiviral vectors that display a T
cell-activating polypeptide
Marielle Maurice,
Els Verhoeyen,
Patrick Salmon,
Didier Trono,
Stephen J. Russell, and
François-Loïc Cosset
From the Laboratoire Vectorologie Rétrovirale et
Thérapie Génique, Unité de Virologie Humaine, U412
INSERM, IFR 74 and ENS de Lyon, France; Department of Genetics and
Microbiology, Faculty of Medicine, University of Geneva, Geneva,
Switzerland; and the Molecular Medicine Program, Mayo Clinic,
Rochester, Minnesota.
In contrast to oncoretroviruses, lentiviruses such as human
immunodeficiency virus 1 (HIV-1) are able to integrate their genetic material into the genome of nonproliferating cells that are
metabolically active. Likewise, vectors derived from HIV-1 can
transduce many types of nonproliferating cells, with the exception of
some particular quiescent cell types such as resting T cells.
Completion of reverse transcription, nuclear import, and subsequent
integration of the lentivirus genome do not occur in these cells unless
they are activated via the T-cell receptor (TCR) or by cytokines or
both. However, to preserve the functional properties of these important gene therapy target cells, only minimal activation with cytokines or
TCR-specific antibodies should be performed during gene transfer. Here
we report the characterization of HIV-1-derived lentiviral vectors
whose virion surface was genetically engineered to display a T
cell-activating single-chain antibody polypeptide derived from the
anti-CD3 OKT3 monoclonal antibody. Interaction of OKT3 IgGs with the
TCR can activate resting peripheral blood lymphocytes (PBLs) by
promoting the transition from G0 to G1 phases
of the cell cycle. Compared to unmodified HIV-1-based vectors,
OKT3-displaying lentiviral vectors strongly increased gene delivery in
freshly isolated PBLs by up to 100-fold. Up to 48% transduction could be obtained without addition of PBL activation stimuli during infection. Taken together, these results show that surface-engineered lentiviral vectors significantly improve transduction of primary lymphocytes by activating the target cells. Moreover these results provide a proof of concept for an approach that may have utility in
various gene transfer applications, including in vivo gene delivery.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
H. J. Kueng, V. M. Leb, D. Haiderer, G. Raposo, C. Thery, S. V. Derdak, K. G. Schmetterer, A. Neunkirchner, C. Sillaber, B. Seed, et al.
General Strategy for Decoration of Enveloped Viruses with Functionally Active Lipid-Modified Cytokines
J. Virol.,
August 15, 2007;
81(16):
8666 - 8676.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Yang, L. Bailey, D. Baltimore, and P. Wang
Targeting lentiviral vectors to specific cell types in vivo
PNAS,
August 1, 2006;
103(31):
11479 - 11484.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Karlsson
Gene therapy: efficient targeting of hematopoietic stem cells
Blood,
November 15, 2005;
106(10):
3333 - 3333.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Verhoeyen, M. Wiznerowicz, D. Olivier, B. Izac, D. Trono, A. Dubart-Kupperschmitt, and F.-L. Cosset
Novel lentiviral vectors displaying "early-acting cytokines" selectively promote survival and transduction of NOD/SCID repopulating human hematopoietic stem cells
Blood,
November 15, 2005;
106(10):
3386 - 3395.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Roszkowski, G. E. Lyons, W. M. Kast, C. Yee, K. Van Besien, and M. I. Nishimura
Simultaneous Generation of CD8+ and CD4+ Melanoma-Reactive T Cells by Retroviral-Mediated Transfer of a Single T-Cell Receptor
Cancer Res.,
February 15, 2005;
65(4):
1570 - 1576.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Verhoeyen, V. Dardalhon, O. Ducrey-Rundquist, D. Trono, N. Taylor, and F.-L. Cosset
IL-7 surface-engineered lentiviral vectors promote survival and efficient gene transfer in resting primary T lymphocytes
Blood,
March 15, 2003;
101(6):
2167 - 2174.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Bartosch, J. Dubuisson, and F.-L. Cosset
Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1-E2 Envelope Protein Complexes
J. Exp. Med.,
March 3, 2003;
197(5):
633 - 642.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Sandrin, B. Boson, P. Salmon, W. Gay, D. Negre, R. Le Grand, D. Trono, and F.-L. Cosset
Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates
Blood,
July 18, 2002;
100(3):
823 - 832.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
